Skip to main content

Table 4 Activity and efficacy according to KRAS genotype (intent-to-treat analysis)

From: Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

  ORR (%) PFS (m)
range
OS (m)
range
KRAS wild-type plus other than c.35 G>A KRAS mutant (44 pts) 81 (CI ± 12) 13 34
   1+-69+ 1+-69+
KRAS wild-type (30 pts) 90 (CI ± 11) 14 38
   1+-69+ 1+-69+
KRAS wild-type/BRAF wild-type (18 pts) 83 (CI ± 14) 13 31
   4-44 8-66+
other than c.35 G>A KRAS mutant (13 pts) 61 (CI ± 30) 12 39
   3-37 8-59+
c.35 G>A KRAS mutant (14 pts) 71 (CI ± 26) 9 14
   1+-60+ 1+-60+
c.35 G>T KRAS mutant (7 pts) 57 (CI ± 40) 12 21
   3-25 11-46+
  1. m, months; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.